Drug Profile
PFK 158
Alternative Names: ACT-PFK-158; PFK-158Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator University of Louisville
- Developer Advanced Cancer Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Glucose modulators; PFKFB3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)
- 31 Dec 2019 Phase-I development is ongoing in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV)